trimetrexate has been researched along with Bone Cancer in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The antifolate drug most commonly used for treating human tumors is methotrexate (MTX), which is utilized widely in first-line treatment protocols of high-grade osteosarcoma (HGOS)." | 4.95 | Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. ( Fanelli, M; Hattinger, CM; Picci, P; Serra, M; Tavanti, E; Vella, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hattinger, CM | 1 |
| Tavanti, E | 1 |
| Fanelli, M | 1 |
| Vella, S | 1 |
| Picci, P | 1 |
| Serra, M | 1 |
1 review available for trimetrexate and Bone Cancer
| Article | Year |
|---|---|
Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Folic Acid Antagonists; Humans; Methotrexate; Neopl | 2017 |